Francisco Javier Ampudia-Blasco (F Javier Ampudia Blasco, F Javier Ampudia-Blasco)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Glycemic Control

Body Mass Index

Top Venues

Diabetes, obesity & metabolism

Journal of diabetes science and technology

Diabetes therapy : research, treatment and education of diabetes and related disorders

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Ana Palanca, Francisco Javier Ampudia-Blasco, José Miguel Calderón, Inmaculada Sauri, Sergio Martinez-Hervás, José Luis Trillo, Josep Redón, José T Real
Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Francisco Javier Ampudia-Blasco, Natalia Duque, Esther Artime, Elena Caveda, Erik Spaepen, Silvia Díaz-Cerezo, Miriam Rubio- de Santos, Daniel Callejo Velasco, Mª Pilar Bahíllo-Curieses
Which people with diabetes are treated with a disposable, half-unit insulin pen? A real-world, retrospective, database study in Spain. Endocrinology, diabetes & metabolism (2023)
Francisco Javier Ampudia-Blasco, Estibaliz Ugarte-Abasolo, Ana Chico, Jorge García-Alemán, Manuel Galan-Barroso
Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project. Journal of diabetes science and technology (2022)
Virginia Bellido-Castañeda, Eva Aguilera, Roque Cardona-Hernandez, Gonzalo Diaz-Soto, Noemi González Pérez de Villar, María J Picón-César, Francisco Javier Ampudia-Blasco
Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes. Journal of diabetes science and technology (2022)
Ana Palanca, Falco van Nes, Felipe Pardo, Francisco Javier Ampudia-Blasco, Chantal Mathieu
Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Diabetes care 45 (3) (2022)
Emma G Wilmot, Kelly L Close, Dubravka Jurišić-Eržen, Daniela Bruttomesso, Francisco Javier Ampudia-Blasco, Zsolt Bosnyak, Aude Roborel de Climens, Grégory Bigot, Anne L Peters, Eric Renard, Lori D Berard, Luis Eduardo Calliari, Jochen Seufert
Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study. Diabetes, obesity & metabolism 23 (8) (2021)
Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m2. Diabetes, obesity & metabolism 23 (3) (2020)
Julio Rosenstock, Francisco Javier Ampudia-Blasco, Robert Lubwama, Xuejun Victor Peng, Anders Boss, Lizheng Shi, Vivian A Fonseca
Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists. Diabetes, obesity & metabolism 22 (12) (2020)